A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Feb 2017 Planned End Date changed from 1 Jan 2018 to 31 Dec 2018.
- 06 Feb 2017 Planned primary completion date changed from 1 Jan 2018 to 31 Dec 2017.